Martin K Bakht

13PUBLICATIONS
64CO-AUTHORS
Molecular targetsPredictive and prognostic markersPharmaceutical delivery technologiesMedical physics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Nov 27, 2025
YM155 Inhibition of Survivin Enhances Carboplatin Efficacy in Metastatic Castration-Resistant Prostate Cancer.

Vicenç Ruiz de Porras, Martin K Bakht, Maria Fernandez-Saorín

|Jul 02, 2025
Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer.

Kei Mizuno, Sheng-Yu Ku, Varadha Balaji Venkadakrishnan

|Nov 20, 2024
Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer.

Shankha S Chatterjee, Juan F Linares, Tania Cid-Diaz

|Aug 08, 2024
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes.

Varadha Balaji Venkadakrishnan, Adam G Presser, Richa Singh

|Jul 08, 2024
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer.

Martin K Bakht, Himisha Beltran

|Feb 26, 2024
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes.

Varadha Balaji Venkadakrishnan, Adam G Presser, Richa Singh

Pageof 3